Stock GMAB GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

Genmab A/S Share Price

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Real-time Estimate Cboe Europe
Other stock markets
 03:11:04 11/12/2024 pm IST 		5-day change 1st Jan Change
1,544.50 DKK -0.77% Intraday chart for Genmab A/S +1.14% -28.26%
09/12 Genmab's Potential Leukemia Treatment Shows Overall Response Rate of 61% in Phase 1/2 Trial MT
09/12 Genmab's Chronic Lymphocytic Leukemia Antibody Shows High Response Rates MT

Valuation: Genmab A/S

Capitalization 10TCr 1.45TCr 1.38TCr 1.28TCr 1.14TCr 2.06TCr 1,23200Cr 2.28TCr 16TCr 5.89TCr 51TCr 5.45TCr 5.33TCr 2,20700Cr P/E ratio 2024 *
18.8x
P/E ratio 2025 * 16.9x
Enterprise value 8.6TCr 1.21TCr 1.15TCr 1.07TCr 951.11Cr 1.72TCr 1,02900Cr 1.9TCr 13TCr 4.92TCr 42TCr 4.55TCr 4.45TCr 1,84400Cr EV / Sales 2024 *
4.06x
EV / Sales 2025 * 3.14x
Free-Float
95.94%
Yield 2024 *
-
Yield 2025 * -
More valuation ratios * Estimated data

Chart: Genmab A/S

Dynamic Chart

Latest news: Genmab A/S

Genmab's Potential Leukemia Treatment Shows Overall Response Rate of 61% in Phase 1/2 Trial 09/12 MT
Genmab's Chronic Lymphocytic Leukemia Antibody Shows High Response Rates 09/12 MT
Genmab Reports High Response Rates in Follow-up Trial Data for Follicular Lymphoma Therapy 09/12 MT
Genmab A/S Announces New Results from the Phase 1b/2 EPCORE NHL-2 Trial 08/12 CI
Scancell Signs New Commercial License Deal With Genmab 04/12 MT
Scancell Holdings plc Announces Genmab Exercises Option to A Second Commercial License Agreement 04/12 CI
Genmab A/S Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 02:30 PM 04/12
JP Morgan lowers target price for Genmab to DKK 1,700 (2,050), reiterates neutral - BN 03/12 FW
Jefferies lowers target price for Genmab to DKK 1,650 (2,150), reiterates Hold 25/11 FW
Goldman Sachs lowers target price for Genmab to DKK 2,425 (2,509), reiterates neutral - BN 20/11 FW
Trump-induced Pharma fears shouldn't be long-lived 19/11Alphavalue
Genmab A/S Presents at Jefferies London Healthcare Conference 2024, Nov-19-2024 03:30 PM 19/11
Deutsche Bank lowers target price for Genmab to DKK 2,250 (2,500), reiterates Buy 12/11 FW
More news

Last Transcript: Genmab A/S

Logo Genmab A/S
Genmab A/S Presents at Citi's 2024 Global Healthcare Conference, Dec-03-2024 02:30 PM
04/12
More transcripts

Analysts' recommendations: Genmab A/S

JP Morgan lowers target price for Genmab to DKK 1,700 (2,050), reiterates neutral - BN 03/12 FW
Jefferies lowers target price for Genmab to DKK 1,650 (2,150), reiterates Hold 25/11 FW
Goldman Sachs lowers target price for Genmab to DKK 2,425 (2,509), reiterates neutral - BN 20/11 FW
Deutsche Bank lowers target price for Genmab to DKK 2,250 (2,500), reiterates Buy 12/11 FW
Carnegie lowers target price for Genmab to DKK 2,658 (2,740), reiterates Buy - BN 12/11 FW
More recommendations

Press Releases: Genmab A/S

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) 09/12 BU
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) 09/12 GL
Genmab A/S - Investigational Epcoritamab Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients with Relapsed or Refractory Follicular Lymphoma 09/12 AQ
Genmab A/S - Investigational Epcoritamab Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia in Preliminary Analysis 09/12 AQ
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis 08/12 AQ
More press releases

News in other languages: Genmab A/S

En Direct des Marchés : Vivendi à la découpe, Crédit Agricole contre-attaque et mariage dans la pub 09/12
Ça baisse plus 09/12
En Direct des marchés : Pluie de résultats en Europe, Qualcomm brille aux Etats-Unis 07/11
Comme un air de déjà-vu 07/11
La bourse chinoise fait n'importe quoi 08/10
More news

Quotes and Performance

1 day-0.32%
1 week+1.63%
Current month+2.00%
1 month-2.23%
3 months-16.00%
6 months-19.04%
Current year-27.77%
More quotes

Course Extremes

1 week
1 529.00
Extreme 1529
1 574.00
1 month
1 431.00
Extreme 1431
1 610.50
Current year
1 431.00
Extreme 1431
2 227.00
1 year
1 431.00
Extreme 1431
2 227.00
3 years
1 431.00
Extreme 1431
3 327.00
5 years
1 082.50
Extreme 1082.5
3 327.00
10 years
327.90
Extreme 327.9
3 327.00
More quotes

Managers and Directors: Genmab A/S

Director TitleAgeSince
Jan van de Winkel CEO
 Chief Executive Officer 63 01/06/2010
Anthony Pagano DFI
 Director of Finance/CFO 46 01/03/2020
Rayne Waller CTO
 Chief Tech/Sci/R&D Officer - 16/08/2024
Manager TitleAgeSince
Anders Gersel Pedersen BRD
 Director/Board Member 73 01/11/2003
Pernille Erenbjerg BRD
 Director/Board Member 57 01/01/2015
Paolo Augusto Paoletti BRD
 Director/Board Member 73 01/01/2015
More insiders

ETFs: Genmab A/S

Name Weight AuM 1st Jan change Investor Rating
XACT NORDEN (UCITS ETF) - SEK ETF XACT NORDEN (UCITS ETF) - SEK
3.64% 203 M€ +14.56%
HAN-GINS TECH MEGATREND EQUAL WEIGHT UCITS ETF - USD ETF HAN-GINS Tech Megatrend Equal Weight UCITS ETF - USD
1.01% 83 M€ +18.16%
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY ETF Nomura NEXT FUNDS International Equity MSCI-KOKUSAI (Yen-Hedged) ETF - JPY
0.75% 20 M€ +16.14% -
VANECK SUSTAINABLE WORLD EQUAL WEIGHT UCITS ETF - EUR ETF VanEck Sustainable World Equal Weight UCITS ETF - EUR
0.56% 772 M€ +16.93%
More ETFs: Genmab A/S

Bio Therapeutic Drugs

Add to a list
Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi. ($)
GENMAB A/S Stock Genmab A/S
-0.32%+1.63%-30.88%-38.21%1.45TCr
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.00%+2.68%+34.01%+125.52%12TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
-1.21%+3.86%-7.34%+16.28%8.38TCr
ARGENX SE Stock argenx SE
-0.89%-1.39%+36.79%+121.12%3.68TCr
BIONTECH SE Stock BioNTech SE
-3.29%+1.09%+12.97%-54.65%2.8TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-1.71%+10.80%-23.72%-58.56%2.29TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-9.69%-8.99%+7.14%-37.17%1.99TCr
SUMMIT THERAPEUTICS INC. Stock Summit Therapeutics Inc.
-3.70%+1.13%+720.55%+262.30%1.33TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
-0.12%+2.81%+9.96%+61.91%1.31TCr
INSMED INCORPORATED Stock Insmed Incorporated
-0.21%+0.26%+159.73%+175.18%1.3TCr
Average -1.98%+1.52%+91.92%+57.37% 3.66TCr
Weighted average by Cap. -1.09%+2.11%+44.04%+63.89%
See all sector performances

Financials

2024 *2025 *
Net sales 2.12TCr 298.32Cr 283.94Cr 263.13Cr 234.04Cr 422.48Cr 25TCr 468.21Cr 3.28TCr 1.21TCr 10TCr 1.12TCr 1.1TCr 45TCr 2.47TCr 348.71Cr 331.9Cr 307.58Cr 273.58Cr 493.85Cr 30TCr 547.3Cr 3.83TCr 1.41TCr 12TCr 1.31TCr 1.28TCr 53TCr
Net income 547.35Cr 77Cr 73Cr 68Cr 61Cr 109.22Cr 6.54TCr 121.04Cr 847.02Cr 312.68Cr 2.69TCr 289.53Cr 283.28Cr 12TCr 624.12Cr 88Cr 84Cr 78Cr 69Cr 124.54Cr 7.46TCr 138.01Cr 965.81Cr 356.53Cr 3.06TCr 330.13Cr 323.01Cr 13TCr
Net Debt -1.7TCr -239.17Cr -227.64Cr -210.96Cr -187.64Cr -338.72Cr -20TCr -375.38Cr -2.63TCr -969.72Cr -8.33TCr -897.92Cr -878.55Cr -36TCr -2.53TCr -355.79Cr -338.65Cr -313.83Cr -279.13Cr -503.88Cr -30TCr -558.42Cr -3.91TCr -1.44TCr -12TCr -1.34TCr -1.31TCr -54TCr
More financial data * Estimated data

Company Profile

Logo Genmab A/S
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.
Employees
2,635
Sector
Biotechnology & Medical Research
Calendar
09:30pm - R&D Day
More about the company

Quotes

Date Price Change Volume
11/24/11 1,547.00 kr -0.61% 10,058
10/24/10 1,556.50 kr -0.32% 76,138
09/24/09 1,561.50 kr +0.81% 85,105
06/24/06 1,549.00 kr -0.16% 56,070
05/24/05 1,551.50 kr +1.50% 77,833

Delayed Quote Nasdaq Copenhagen, December 10, 2024 at 09:50 pm IST

More quotes

Income Statement and Estimates

income-statement-evolution-chart GENMAB-A-S More financial data

Ratings

Trading Rating
Investor Rating
ESG Refinitiv
A-
surperformance-ratings-light-chart GENMAB-A-SMore Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
1,556.50DKK
Average target price
2,345.00DKK
Spread / Average Target
+50.66%
Consensus
Profit revisions
estimates-change-chart GENMAB-A-S Estimate revisions

Quarterly revenue - Rate of surprise

quality-estimates-chart GENMAB-A-S Company calendar
  1. Stock Market
  2. Equities
  3. GMAB Stock
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition